<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860482</url>
  </required_header>
  <id_info>
    <org_study_id>243GERD13003</org_study_id>
    <nct_id>NCT01860482</nct_id>
  </id_info>
  <brief_title>The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD</brief_title>
  <official_title>An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients
      with refractory reflux esophagitis to the prior standard PPIs regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to onset of first 1Day Heartburn free, Days</measure>
    <time_frame>up to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of first 2Days Heartburn free, Days</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1Day Heartburn free days, %</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in Daytime of first Heartburn free, Days</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in Nighttime of first Heartburn free, Days</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Heartburn Improvement Rate, %</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daytime and Nighttime Heartburn Score Change at W4</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daytime and Nighttime Heartburn Score Change at W8</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Reflux Esophagitis</condition>
  <arm_group>
    <arm_group_label>Newrabell single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newrabell® Tablet 10mg b.i.d PO during 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Newrabell® Tablet 10mg</intervention_name>
    <arm_group_label>Newrabell single arm</arm_group_label>
    <other_name>Rabeprazole sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female aged ≥ 20 years

          2. Reflux esophagitis with erosion or ulceration confirmed by endoscopic exam.

          3. Refractory reflux esophagitis to PPIs standard treatment as follows

               1. Ongoing heartburn symptom with or without these GERD-related symptoms :
                  Regurgitation, Non-cardiac chest pain, Epigastric pain, Belching, Bloating,
                  Satiety, Sore throat, Cough, Laryngitis, Hoarseness, Nausea, Vomiting, Dysphagia,
                  Odynophagia, Weight loss

               2. Ongoing heartburn symptom with or without erosion ≥ grade A according to LA
                  Classification

          4. Ongoing heartburn symptoms ≥ 2 days during 1week right before administering first dose
             of IP

          5. Decided to participate and signed on an informed consent form willingly

        Exclusion Criteria:

          1. Existence of upper gastrointestinal bleeding or active gastroduodenal ulcer at
             screening

          2. History of operation in esophagus, stomach or duodenum

          3. The following medical history

               1. Primary esophageal motility disease, Achalasia, Scleroderma, Esophageal/pyloric
                  stricture, Primary esophageal spasm

               2. Barrett's esophagus ≥ 3 cm

               3. Zollinger-Ellison syndrome

               4. Infectious or inflammatory bowel disease, Severe malabsorption

          4. Severe chronic heart failure, cardiovascular disease, renal failure, COPD, asthma,
             liver cirrhosis

          5. History of cancer within 5 years, except completely recovered skin cancer

          6. ALT or AST ≥ Upper limit of normal range X 3

          7. Need antibiotics due to severe infection

          8. Severe medical disease that needs these prohibited medication

               -  Anticoagulant(Heparin, Warfarin, etc.), High dose of aspirin(&gt;325mg/d),
                  Digitalis(Digoxin, etc.), Diuretics, Atazanavir, NSAIDs or Steroids

          9. Use PPIs or H2RA medicine within 1 week before administering first dose of IP, or need
             other PPIs or H2RA medicine during trial period

         10. Allergy or hypersensitivity to IP or similar chemical structure(Benzimidazol
             derivatives, etc.)

         11. Pregnant or breast-feeding women

         12. Conversation impairment because of alcohol, drug addiction or mental illness, etc.

         13. Administration of other IP within 28 days

         14. Inability to record heartburn diary card

         15. In investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jongsun Rew, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sungbum Cho, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>Donggu, Jebongro</state>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>Hwasun-eup,Hwasun-gun</state>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory Reflux Esophagitis</keyword>
  <keyword>GERD</keyword>
  <keyword>Phase 4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

